129 related articles for article (PubMed ID: 38291279)
1. Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial.
Nichols RM; Macpherson L; Patel DR; Yeh WW; Peppercorn A
Infect Dis Ther; 2024 Feb; 13(2):401-411. PubMed ID: 38291279
[TBL] [Abstract][Full Text] [Related]
2. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gottlieb RL; Nirula A; Chen P; Boscia J; Heller B; Morris J; Huhn G; Cardona J; Mocherla B; Stosor V; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Klekotka P; Shen L; Skovronsky DM
JAMA; 2021 Feb; 325(7):632-644. PubMed ID: 33475701
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load.
Dougan M; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Blomkalns A; Adams AC; Van Naarden J; Custer KL; Knorr J; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Sabo J; Patel DR; Dabora MC; Williams M; Klekotka P; Shen L; Skovronsky DM; Nirula A
Clin Infect Dis; 2022 Aug; 75(1):e440-e449. PubMed ID: 34718468
[TBL] [Abstract][Full Text] [Related]
4. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
[TBL] [Abstract][Full Text] [Related]
5. Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.
Dougan M; Nirula A; Azizad M; Mocherla B; Gottlieb RL; Chen P; Hebert C; Perry R; Boscia J; Heller B; Morris J; Crystal C; Igbinadolor A; Huhn G; Cardona J; Shawa I; Kumar P; Adams AC; Van Naarden J; Custer KL; Durante M; Oakley G; Schade AE; Holzer TR; Ebert PJ; Higgs RE; Kallewaard NL; Sabo J; Patel DR; Dabora MC; Klekotka P; Shen L; Skovronsky DM;
N Engl J Med; 2021 Oct; 385(15):1382-1392. PubMed ID: 34260849
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial.
Upadhyaya HP; Chien JY; Long AJ; Bohm MS; Kallewaard NL; Macpherson LF; Patel DR; Hufford MM; Krull CJ; Ang JY; Chen P; Muller WJ; Potts JA; Quinn T; Williams M;
Infect Dis Ther; 2023 Jul; 12(7):1861-1873. PubMed ID: 37329415
[TBL] [Abstract][Full Text] [Related]
7. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
Front Immunol; 2021; 12():790469. PubMed ID: 34956222
[TBL] [Abstract][Full Text] [Related]
8. Emulation of a Target Trial From Observational Data to Compare Effectiveness of Casirivimab/Imdevimab and Bamlanivimab/Etesevimab for Early Treatment of Non-Hospitalized Patients With COVID-19.
Mazzotta V; Cozzi-Lepri A; Colavita F; Lanini S; Rosati S; Lalle E; Mastrorosa I; Cimaglia C; Vergori A; Bevilacqua N; Lapa D; Mariano A; Bettini A; Agrati C; Piselli P; Girardi E; Castilletti C; Garbuglia AR; Vaia F; Nicastri E; Antinori A
Front Immunol; 2022; 13():868020. PubMed ID: 35514955
[TBL] [Abstract][Full Text] [Related]
9. Effects of bamlanivimab alone or in combination with etesevimab on subsequent hospitalization and mortality in outpatients with COVID-19: a systematic review and meta-analysis.
Tai YL; Lee MD; Chi H; Chiu NC; Lei WT; Weng SL; Liu LY; Chen CC; Huang SY; Huang YN; Lin CY
PeerJ; 2023; 11():e15344. PubMed ID: 37180576
[TBL] [Abstract][Full Text] [Related]
10. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
[TBL] [Abstract][Full Text] [Related]
11. PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.
Ernest CS; Chien JY; Patel DR; Chigutsa E
CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):721-730. PubMed ID: 35289125
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 neutralizing antibodies for COVID-19: Outcomes for bamlanivimab versus bamlanivimab-etesevimab combination in a racially diverse cohort of patients with significant comorbidities.
Monday LM; Brar I; Alangaden G; Ramesh MS
J Clin Pharm Ther; 2022 Sep; 47(9):1438-1443. PubMed ID: 35633095
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of adverse events of bamlanivimab, bamlanivimab/etesevimab used for COVID-19 based on FAERS database.
Zhao Y; Wang H; Zhang Q; Hu Y; Xu Y; Liu W
Expert Opin Drug Saf; 2023 Apr; 22(4):331-338. PubMed ID: 36178050
[TBL] [Abstract][Full Text] [Related]
15. The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.
Huang DT; McCreary EK; Bariola JR; Wadas RJ; Kip KE; Marroquin OC; Koscumb S; Collins K; Shovel JA; Schmidhofer M; Wisniewski MK; Sullivan C; Yealy DM; Axe M; Nace DA; Haidar G; Khadem T; Linstrum K; Snyder GM; Seymour CW; Montgomery SK; McVerry BJ; Berry L; Berry S; Meyers R; Weissman A; Peck-Palmer OM; Wells A; Bart R; Albin DL; Minnier T; Angus DC
Trials; 2021 May; 22(1):363. PubMed ID: 34034784
[TBL] [Abstract][Full Text] [Related]
16. Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19: A Phase 2 Randomized Clinical Trial.
Chew KW; Moser C; Daar ES; Wohl DA; Li JZ; Coombs R; Ritz J; Giganti M; Javan AC; Li Y; Malvestutto C; Klekotka P; Price K; Nirula A; Fischer W; Bala V; Ribeiro RM; Perelson AS; Fletcher CV; Eron JJ; Currier JS; Hughes MD; Smith DM;
medRxiv; 2021 Dec; ():. PubMed ID: 34981077
[TBL] [Abstract][Full Text] [Related]
17. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
[TBL] [Abstract][Full Text] [Related]
18. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
Elife; 2022 Nov; 11():. PubMed ID: 36413383
[TBL] [Abstract][Full Text] [Related]
19. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
[TBL] [Abstract][Full Text] [Related]
20. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B; Montague BT; Frank I; McCulloh RJ; Fichtenbaum CJ; Lipson B; Gabra N; Ramirez JA; Thai C; Chege W; Gomez Lorenzo MM; Sista N; Farrior J; Clement ME; Brown ER; Custer KL; Van Naarden J; Adams AC; Schade AE; Dabora MC; Knorr J; Price KL; Sabo J; Tuttle JL; Klekotka P; Shen L; Skovronsky DM;
JAMA; 2021 Jul; 326(1):46-55. PubMed ID: 34081073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
